ELOXX PHARMACEUTICALS, INC. Proceeds from Long-Term Debt Issued
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Proceeds from Long-Term Debt Issued of $0 for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $1.88M.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $390.00K.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2021 was $11.87M, a 1389.84% increase from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2020 was $797.00K, a 94.69% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2019 was $15.00M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11 | $0.00 S-1 · filed 2026-09-11 | ||
| 2026-03-31 | $0.00 S-1/A · filed 2026-06-04 | |||
| 2025-12-31 | $2.87M S-1 · filed 2026-09-11 | |||
| 2025-06-30 | $1.88M derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11 | $2.27M S-1 · filed 2026-09-11 | ||
| 2025-03-31 | $390.00K S-1/A · filed 2026-06-04 | |||
| 2024-12-31 | $3.67M S-1 · filed 2026-09-11 | |||
| 2023-12-31 | $0.00 S-1 · filed 2026-09-11 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | |||
| 2021-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $11.87M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $11.91M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $797.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $797.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $797.00K 10-Q · filed 2021-08-16 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 derived: sum of 3 quarters · filed 2022-03-30 | $15.00M 10-K · filed 2022-03-30 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $15.00M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $15.00M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $15.00M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |